Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) has been assigned a $2.00 price target by research analysts at Roth Capital in a note issued to investors on Monday. The firm presently has a “buy” rating on the biotechnology company’s stock. Roth Capital’s price target would indicate a potential upside of 471.43% from the stock’s previous close.

A number of other equities analysts have also recently commented on RTTR. Maxim Group reiterated a “hold” rating on shares of Ritter Pharmaceuticals in a report on Wednesday, July 5th. Zacks Investment Research cut Ritter Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, August 8th. Finally, Chardan Capital reduced their price target on Ritter Pharmaceuticals from $3.50 to $1.50 and set a “buy” rating for the company in a report on Tuesday, August 8th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $2.92.

Ritter Pharmaceuticals (NASDAQ RTTR) traded down 2.56% during trading on Monday, hitting $0.35. The company had a trading volume of 499,475 shares. Ritter Pharmaceuticals has a one year low of $0.32 and a one year high of $3.75. The stock has a 50-day moving average of $0.44 and a 200-day moving average of $0.44. The stock’s market capitalization is $5.16 million.

Ritter Pharmaceuticals (NASDAQ:RTTR) last announced its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.14) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.14). On average, equities analysts anticipate that Ritter Pharmaceuticals will post ($0.42) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This article was published by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/10/24/ritter-pharmaceuticals-inc-rttr-given-a-2-00-price-target-at-roth-capital.html.

A hedge fund recently raised its stake in Ritter Pharmaceuticals stock. KCG Holdings Inc. grew its stake in shares of Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) by 259.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 105,409 shares of the biotechnology company’s stock after acquiring an additional 76,046 shares during the period. KCG Holdings Inc. owned 0.91% of Ritter Pharmaceuticals worth $150,000 at the end of the most recent quarter. 2.25% of the stock is owned by hedge funds and other institutional investors.

Ritter Pharmaceuticals Company Profile

Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.

Analyst Recommendations for Ritter Pharmaceuticals (NASDAQ:RTTR)

Receive News & Ratings for Ritter Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.